GSK oncology portfolio gains momentum with new drug approvals and study data
GlaxoSmithKline reported multiple positive developments for its cancer medicines in Madrid during a recent week.
Recent regulatory and clinical wins
The company secured approval for an existing cancer drug covering another tumor type. GSK also unveiled initial results from a global study of a next-generation chemotherapy agent. Additionally, a licensed medicine received attention during a presidential session at a major oncology conference.
Upcoming lung cancer treatment
The firm is currently awaiting another expected approval for a new lung cancer drug in the coming weeks. This progress marks a significant recovery after the company left the oncology field a decade ago.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.